RESUMEN
Despite being the initial choice for treating toxoplasmosis, sulfadiazine and pyrimethamine have limited effectiveness in eliminating the infection and were linked to a variety of adverse effects. Therefore, the search for new effective therapeutic strategies against toxoplasmosis is still required. The current work is the first research to assess the efficacy of spiramycin-loaded maltodextrin nanoparticles (SPM-loaded MNPs) as a novel alternative drug therapy against toxoplasmosis in a murine model. Fifty laboratory-bred Swiss albino mice were divided into five groups: normal control group (GI, n = 10), positive control group (GII, n = 10), orally treated with spiramycin (SPM) alone (GIII, n = 10), intranasal treated with SPM-loaded MNPs (GIV, n = 10), and orally treated with SPM-loaded MNPs (GV, n = 10). Cysts of Toxoplasma gondii ME-49 strain were used to infect the mice. Tested drugs were administered 2 months after the infection. Drug efficacy was assessed by counting brain cysts, histopathological examination, and measures of serum CD19 by flow cytometer. The orally treated group with SPM-loaded MNPs (GV) showed a marked reduction of brain cyst count (88.7%), histopathological improvement changes, and an increasing mean level of CD19 (80.2%) with significant differences. SPM-loaded MNPs showed potent therapeutic effects against chronic toxoplasmosis. Further research should be conducted to assess it in the treatment of human toxoplasmosis, especially during pregnancy.
Asunto(s)
Modelos Animales de Enfermedad , Nanopartículas , Polisacáridos , Espiramicina , Toxoplasmosis Animal , Animales , Espiramicina/uso terapéutico , Espiramicina/administración & dosificación , Ratones , Polisacáridos/administración & dosificación , Polisacáridos/uso terapéutico , Polisacáridos/farmacología , Nanopartículas/química , Toxoplasmosis Animal/tratamiento farmacológico , Toxoplasma/efectos de los fármacos , Femenino , Encéfalo/parasitología , Encéfalo/patología , Antiprotozoarios/administración & dosificación , Antiprotozoarios/uso terapéutico , Toxoplasmosis/tratamiento farmacológico , Toxoplasmosis/parasitología , Portadores de FármacosRESUMEN
BACKGROUND: Toxoplasmosis is a parasitic infection caused by Toxoplasma gondii and is responsible for gestational and congenital infections worldwide. The current standard therapy is based on the administration of Spiramycin to prevent trans-placental transmission. Other therapies are being studied to reduce the rates of foetal transmission and symptomatic congenital infection. OBJECTIVES: We report our long-standing experience in maternal toxoplasmosis infection treatment using a combination of Spiramycin-Cotrimoxazole, assessing its effectiveness in preventing vertical transmission compared to the expected incidence of congenital infection. METHODS: We retrospectively collected cases of pregnant women referred to our centre for suspected toxoplasmosis infection according to Lebech criteria, treated with Spiramycin-Cotrimoxazole. RESULTS: Of 1364 women referred to our centre, postnatal follow-up of primary toxoplasmosis was available in 562 cases (73.9%). The overall vertical transmission rate was 3.4% in women treated immediately with Spiramycin-Cotrimoxazole after the diagnosis of infection. In comparison, it was 7.7% in women undergoing the same therapy but late or with poor compliance. The foetal transmission rate was 71.4% in untreated cases. All the infected newborns of mother treated adequately with Spiramycin-Cotrimoxazole were asymptomatic afterbirth, while 6/21 infected infants of the inadequate Spiramycin-Cotrimoxazole therapy group had postnatal sequelae (28.5%). The incidence of transmission after appropriate Spiramycin-Cotrimoxazole therapy was significantly lower than the expected rate reported in literature. CONCLUSIONS: A combination of Spiramycin and Cotrimoxazole is safe and effective in preventing foetal congenital toxoplasmosis and reducing sequelae in case of in-utero infection. The timing and adherence to the therapy are crucial to lowering the risk of congenital infection and neonatal morbidity.
Asunto(s)
Transmisión Vertical de Enfermedad Infecciosa , Complicaciones Parasitarias del Embarazo , Espiramicina , Centros de Atención Terciaria , Toxoplasmosis Congénita , Combinación Trimetoprim y Sulfametoxazol , Humanos , Espiramicina/uso terapéutico , Femenino , Embarazo , Toxoplasmosis Congénita/prevención & control , Toxoplasmosis Congénita/tratamiento farmacológico , Toxoplasmosis Congénita/epidemiología , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Estudios Retrospectivos , Combinación Trimetoprim y Sulfametoxazol/uso terapéutico , Recién Nacido , Complicaciones Parasitarias del Embarazo/prevención & control , Complicaciones Parasitarias del Embarazo/tratamiento farmacológico , Complicaciones Parasitarias del Embarazo/epidemiología , Adulto , Quimioterapia Combinada , Antibacterianos/uso terapéutico , Toxoplasmosis/prevención & control , Toxoplasmosis/transmisión , Toxoplasmosis/tratamiento farmacológico , Toxoplasmosis/epidemiología , Antiprotozoarios/uso terapéuticoRESUMEN
PURPOSE: Searching for a novel early diagnostic biomarker for toxoplasmosis, real-time-PCR was currently used to measure the serum mmu-miR-511-5p level in male Swiss-albino mice infected with either; ME49 or RH Toxoplasma gondii (T. gondii) strains. METHODS: Three mice groups were used; (GI) constituted the non-infected control group, while (GII) and (GIII) were experimentally infected with ME49 or RH strains, respectively. GII mice were orally infected using 10 or 20 ME49 cysts (ME-10 and ME-20), both were subdivided into; non-treated (ME-10-NT and ME-20-NT) and were further subdivided into; immunocompetent (ME-10-IC and ME-20-IC) [euthanized 3-days, 1, 2, 6 or 8-weeks post-infection (PI)], and immunosuppressed using two Endoxan® injections (ME-10-IS and ME-20-IS) [euthanized 6- or 8-weeks PI], and spiramycin-treated (ME-10-SP and ME-20-SP) that received daily spiramycin, for one-week before euthanasia. GIII mice individually received 2500 intraperitoneal RH strain tachyzoites, then, were subdivided into; non-treated (RH-NT) [euthanized 3 or 5-days PI], and spiramycin-treated (RH-SP) that were euthanized 5 or 10-days PI (refer to the graphical abstract). RESULTS: Revealed significant upregulation of mmu-miR-511-5p in GII, one-week PI, with gradually increased expression, reaching its maximum 8-weeks PI, especially in ME-20-NT group that received the higher infective dose. Immunosuppression increased the upregulation. Contrarily, treatment caused significant downregulation. GIII recorded significant upregulation 3-days PI, yet, treatment significantly decreased this expression. CONCLUSION: Serum mmu-miR-511-5p is a sensitive biomarker for early diagnosis of ME49 and RH infection (as early as one-week and 3-days, respectively), and its expression varies according to T. gondii infective dose, duration of infection, spiramycin-treatment and host immune status.
Asunto(s)
Biomarcadores , MicroARNs , Toxoplasma , Toxoplasmosis Animal , Animales , MicroARNs/sangre , MicroARNs/genética , Ratones , Masculino , Toxoplasma/inmunología , Toxoplasma/genética , Biomarcadores/sangre , Toxoplasmosis Animal/inmunología , Toxoplasmosis Animal/diagnóstico , Toxoplasmosis Animal/tratamiento farmacológico , Espiramicina , Modelos Animales de Enfermedad , Toxoplasmosis/diagnóstico , Toxoplasmosis/inmunología , Toxoplasmosis/tratamiento farmacológicoRESUMEN
Objective: Congenital toxoplasmosis (CT) can have severe early and late sequelae in children. In this study, we aimed to evaluate the demographic, clinical, treatment characteristics of patients diagnosed with congenital Toxoplasma infection and to highlight the long-term complications of the patients. Methods: Patients with CT were included in this study who were followed between 2010 and 2022 in Cukurova University Medical Faculty Hospital. Demographic, clinical and treatment characteristics were searched retrospectively. In the diagnosis of maternal and CT, Toxoplasma IgM, IgG, IgG avidity, T. gondii polymerase chain reaction tests were used along with clinical and symptoms. Results: Eighteen children (two twins) with CT and their mothers (n=16) were included in the study. Median age was 1 month. Ten (55.5%) of the children were male. CT diagnosis was made during pregnancy in 7 mothers (resulting in 8 babies) and postnatally in 9 mothers (resulting in 10 babies). The mothers of 5 (31.1%) babies with CT received spiramycin treatment during pregnancy. Three (60%) of 5 pregnant women who received spiramycin were diagnosed in the first trimester, 4 (80%) of the babies did not have any sequale and only 1 (20%) had microphthalmia. Ocular involvement was the most common presentation of the disease occured in 10 patients (55.5%), hydrocephalus and intracranial calcification developed in five patients (27.7%). Hearing loss developed in 2 (11.1%) patients. During the follow-up period, seizures developed in 3 patients (16.6%), microcephaly in 2 patients (11.1%), and neurodevolopmental retardation in 7 patients (38.8%), two of the patients had severe mental retardation. One (5.5%) patient with hydrocephalus died at 36 months of age due to complications after ventriculoperitoneal shunt application. Conclusion: In our study, we observed severe sequelae in vision, hearing, and neurodevelopmental aspects in children diagnosed with CT at birth and during follow-ups. Early diagnosis and treatment of infants, along with the detection of Toxoplasma infection during pregnancy, are essential in preventing severe sequelae that may arise due to CT.
Asunto(s)
Hidrocefalia , Espiramicina , Toxoplasmosis Congénita , Embarazo , Recién Nacido , Lactante , Niño , Humanos , Femenino , Masculino , Estudios Retrospectivos , Toxoplasmosis Congénita/complicaciones , Toxoplasmosis Congénita/diagnóstico , Toxoplasmosis Congénita/tratamiento farmacológico , Inmunoglobulina GRESUMEN
Bitespiramycin, has been shown to have a therapeutic effect against respiratory tract inflammation, including a potential effect against COVID-19. A current clinical trial in China showed that bitespiramycin was an effective treatment for severe pneumonia and intracranial infection. However, there is lack of an analytical method to elucidate the distribution of bitespiramycin. In this study, a highly sensitive, rapid and reliable UPLC-MS/MS method was developed to comprehensively characterize the bitespiramycin distribution in various bio-samples, which is significantly improved upon the published work. A rapid sample preparation method was developed by using n-butanol as the solvent to extract bitespiramycin from different bio-samples. The extract was then directly analyzed by UPLC-MS/MS coupled with an alkaline-resistant column after centrifugation which avoids the time-consuming concentration process under nitrogen and redissolution. The method was employed to accurately quantify bitespiramycin and its metabolites in rat plasma, tissues, and human cerebrospinal fluid. Notably, the presence of bitespiramycin and its metabolites was identified for the first time in various rat organs including brain, testis, bladder and prostate as well as in human cerebrospinal fluid. This newly developed approach shows great promise for drug distribution assays including other antibiotics and can help elucidate the ADME of bitespiramycin.
Asunto(s)
Cromatografía Líquida con Espectrometría de Masas , Espiramicina/análogos & derivados , Masculino , Ratas , Humanos , Animales , Cromatografía Liquida/métodos , Espectrometría de Masas en Tándem/métodos , Cromatografía Líquida de Alta Presión/métodosRESUMEN
Carrimycin (CA), sanctioned by China's National Medical Products Administration (NMPA) in 2019 for treating acute bronchitis and sinusitis, has recently been observed to exhibit multifaceted biological activities, encompassing anti-inflammatory, antiviral, and anti-tumor properties. Despite these applications, its efficacy in sepsis treatment remains unexplored. This study introduces a novel function of CA, demonstrating its capacity to mitigate sepsis induced by lipopolysaccharide (LPS) and cecal ligation and puncture (CLP) in mice models. Our research employed in vitro assays, real-time quantitative polymerase chain reaction (RT-qPCR), and RNA-seq analysis to establish that CA significantly reduces the levels of pro-inflammatory cytokines, namely tumor necrosis factor-alpha (TNF-α), interleukin 1 beta (IL-1ß), and interleukin 6 (IL-6), in response to LPS stimulation. Additionally, Western blotting and immunofluorescence assays revealed that CA impedes Nuclear Factor Kappa B (NF-κB) activation in LPS-stimulated RAW264.7 cells. Complementing these findings, in vivo experiments demonstrated that CA effectively alleviates LPS- and CLP-triggered organ inflammation in C57BL/6 mice. Further insights were gained through 16S sequencing, highlighting CA's pivotal role in enhancing gut microbiota diversity and modulating metabolic pathways, particularly by augmenting the production of short-chain fatty acids in mice subjected to CLP. Notably, a comparative analysis revealed that CA's anti-inflammatory efficacy surpasses that of equivalent doses of aspirin (ASP) and TIENAM. Collectively, these findings suggest that CA exhibits significant therapeutic potential in sepsis treatment. This discovery provides a foundational theoretical basis for the clinical application of CA in sepsis management.
Asunto(s)
Lipopolisacáridos , Sepsis , Espiramicina/análogos & derivados , Ratones , Animales , Lipopolisacáridos/efectos adversos , Ratones Endogámicos C57BL , Factor de Necrosis Tumoral alfa/metabolismo , Interleucina-6 , Punciones , Sepsis/metabolismo , Antiinflamatorios/farmacología , Antiinflamatorios/uso terapéutico , Modelos Animales de EnfermedadRESUMEN
BACKGROUND: Periodontitis is a microbially induced disease destroying structures anchoring teeth to jaw bones. Although metronidazole in combination with spiramycin is the effective conventional treatment of stage III grade C periodontitis, it has several systemic side effects. Laser therapy is widely used nowadays as an adjunct to scaling and root planing (SRP) to modulate inflammatory host response and eradicate microbes, due to bactericidal and detoxifying effects. Since microbiological analysis is one of the diagnostic methods identifying periodontal risk; our research aimed to investigate the efficacy of intra-pocket application of diode laser (980 nm) versus antibiotic therapy in enhancing clinical and microbiological parameters in stage III grade C periodontitis. METHODS: A randomized controlled clinical trial was conducted on fifty patients with stage III grade C periodontitis, divided equally into two groups. We managed test group by SRP with intra-pocket application of diode laser (980 nm) and the control group by SRP with systemic antibiotic administration (spiramycin and metronidazole). Then, we measured periodontal pocket depth (PPD) and clinical attachment loss (CAL) for both groups, before treatment (baseline), four and twelve weeks after. Moreover, we collected gingival crevicular fluid from both groups at baseline, four and twelve weeks after treatment and analyzed by real-time polymerase chain reaction to detect the relative count of Aggregatibacter actinomycetemcomitans and Porhyromonas gingivalis. RESULTS: Compared to baseline, all assessed clinical and microbiological parameters attested improvement at the end of the study period in each group individually with no significant difference between the two studied groups. Although, at twelve weeks, flare up of bacterial levels was detected with systemic antibiotic administration. CONCLUSION: Laser therapy can be considered as an effective treatment modality in stage III grade C periodontitis, avoiding the systemic antibiotic side effects and solving the recurrence problems due to bacterial resistance by long term usage. TRIAL REGISTRATION: NCT05222737 retrospectively on 03/02/2022, Clinicaltrial.gov.
Asunto(s)
Periodontitis Crónica , Periodontitis , Espiramicina , Humanos , Metronidazol/uso terapéutico , Espiramicina/uso terapéutico , Láseres de Semiconductores/uso terapéutico , Estudios Retrospectivos , Estudios de Seguimiento , Periodontitis/tratamiento farmacológico , Periodontitis/microbiología , Antibacterianos/uso terapéutico , Raspado Dental/métodos , Aplanamiento de la Raíz/métodos , Periodontitis Crónica/terapiaRESUMEN
Ocular toxoplasmosis is the most common cause of infectious posterior uveitis. Available literature is still conflicting regarding the incidence of recurrence during pregnancy as various calculations were employed in the different published studies. Although earlier reports have suggested a difference in presentation and an increase in severity during pregnancy, newer studies appear to show otherwise. Further diagnostic testing, including serologic and intraocular fluid sampling, may be indicated to increase the diagnostic accuracy in this special population of patients. The management of ocular toxoplasmosis during pregnancy is challenging as the foetus is additionally considered in the choice of treatment. Traditionally preferred anti-toxoplasmosis regimens containing antifolate drugs, such as pyrimethamine and trimethoprim-sulfamethoxazole, cannot be used routinely in pregnant patients, especially during the first trimester. This review includes literature on alternative treatments for ocular toxoplasmosis during pregnancy, including spiramycin and intravitreal treatment options.
Asunto(s)
Toxoplasmosis Ocular , Humanos , Toxoplasmosis Ocular/tratamiento farmacológico , Toxoplasmosis Ocular/diagnóstico , Embarazo , Femenino , Antiprotozoarios/uso terapéutico , Complicaciones Parasitarias del Embarazo/tratamiento farmacológico , Complicaciones Parasitarias del Embarazo/diagnóstico , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Complicaciones Infecciosas del Embarazo/diagnóstico , Espiramicina/uso terapéutico , Antibacterianos/uso terapéutico , Inyecciones IntravítreasRESUMEN
Carrimycin (CAM) is a new antibiotics with isovalerylspiramycins (ISP) as its major components. It is produced by Streptomyces spiramyceticus integrated with a heterogenous 4″-O-isovaleryltransferase gene (ist). However, the present CAM producing strain carries two resistant gene markers, which makes it difficult for further genetic manipulation. In addition, isovalerylation of spiramycin (SP) could be of low efficiency as the ist gene is located far from the SP biosynthesis gene cluster. In this study, ist and its positive regulatory gene acyB2 were inserted into the downstream of orf54 gene neighboring to SP biosynthetic gene cluster in Streptomyces spiramyceticus 1941 by using the CRISPR-Cas9 technique. Two new markerless CAM producing strains, 54IA-1 and 54IA-2, were obtained from the homologous recombination and plasmid drop-out. Interestingly, the yield of ISP in strain 54IA-2 was much higher than that in strain 54IA-1. Quantitative real-time PCR assay showed that the ist, acyB2 and some genes associated with SP biosynthesis exhibited higher expression levels in strain 54IA-2. Subsequently, strain 54IA-2 was subjected to rifampicin (RFP) resistance selection for obtaining high-yield CAM mutants by ribosome engineering. The yield of ISP in mutants resistant to 40 μg/mL RFP increased significantly, with the highest up to 842.9 μg/mL, which was about 6 times higher than that of strain 54IA-2. Analysis of the sequences of the rpoB gene of these 7 mutants revealed that the serine at position 576 was mutated to alanine existed in each sequenced mutant. Among the mutants carrying other missense mutations, strain RFP40-6-8 which carries a mutation of glutamine (424) to leucine showed the highest yield of ISP. In conclusion, two markerless novel CAM producing strains, 54IA-1 and 54IA-2, were successfully developed by using CRISPR-Cas9 technique. Furthermore, a novel CAM high-yielding strain RFP40-6-8 was obtained through ribosome engineering. This study thus demonstrated a useful combinatory approach for improving the production of CAM.
Asunto(s)
Sistemas CRISPR-Cas/genética , Ingeniería Genética , Ribosomas , Espiramicina , Streptomyces/genéticaRESUMEN
A toxoplasmose é uma doença proveniente do Toxoplasma gondii, um protozoário que tem os felinos como seu hospedeiro definitivo e os mamíferos e aves como seu hospedeiro intermediário. Tem um curso benigno e autolimitado quando acomete um indivíduo imunocompetente, no entanto a infecção durante a gestação acarreta até 50% de chance de toxoplasmose congênita, podendo causar danos severos ao feto. A virulência dos genótipos encontrados nas Américas Central e do Sul é a mais alta, comparada a Europa e América do Norte, tendo a doença um comportamento mais agressivo. Os estudos relatam a diminuição da infecção fetal em até 60% com o uso da espiramicina, usada ainda na profilaxia. Este artigo discute sobre a triagem materna pré-natal e sua necessidade, a profilaxia e o tratamento da infecção fetal ainda intraútero, com o objetivo de diminuir a transmissão vertical e as sequelas neonatais com suas implicações ao longo da vida.(AU)
Toxoplasmosis it is a disease originating from Toxoplasma gondii, a protozoan that has felines at as ultimate host and mammals and birds at as intermediate host. Has a benign and self-limiting course when affects immunocompetent individual, however, infection during pregnancy leads 50% chance of congenital toxoplasmosis and can cause severe damage to the fetus. The virulence of genotypes found in Central and South America is the highest compared to Europe and North America, having the disease a more aggressive behavior. Studies report a reduction in fetal infection 60% with the use spiramycin still used for prophylaxis. This article discusses prenatal maternal screening, prophylaxis and treatment of fetal infection still in utero with the objective of decreasing vertical transmission and neonatal sequelae with their lifelong implications.(AU)
Asunto(s)
Humanos , Femenino , Embarazo , Toxoplasma , Toxoplasmosis Congénita/diagnóstico , Toxoplasmosis Congénita/prevención & control , Toxoplasmosis Congénita/tratamiento farmacológico , Atención Prenatal , Pirimetamina , Sulfadiazina/uso terapéutico , Inmunoglobulina A , Inmunoglobulina G , Inmunoglobulina M , Espiramicina/uso terapéutico , Feto , Amniocentesis , Líquido Amniótico/parasitologíaRESUMEN
Introducción. La Toxoplasmosis congénita constituye una causa significativa de morbi-mortalidad neonatal en países de bajos ingresos como Colombia. Puede originar prematuridad, secuelas patológicas y pérdida fetal. El tamizaje en las gestantes y, a su vez, un tratamiento oportuno y adecuado disminuye la transmisión vertical y sus nefastas secuelas. El objetivo es presentar evidencia científica actualizada sobre el tratamiento farmacológico de la Toxoplasmosis Congénita. Metodología. Se realizó una búsqueda no sistemática en bases de datos: Pubmed, Medline, Clinical Key y Springer. Se incluyeron artículos originales y de revisión de tema publicados desde enero de 2014 hasta abril de 2019. División de los temas tratados. se abordan la fisiopatología y clínica, el abordaje diagnóstico, alternativas de prevención y tratamiento. Conclusiones. En la actualidad la terapia farmacológica es limitada, los esquemas de manejos se basan en espiramicina o la combinación de sulfadiazina/pirimetamina y ácido folínico; estas moléculas no son del todo bien toleradas y presentan un amplio espectro de reacciones adversas secundario a sus efectos tóxicos; resulta necesario la ejecución de estudios aleatorizados para evaluar su efectividad. Cómo citar: Rueda-Paez YS, Valbuena-Ruiz L, Quintero-Pimiento N, Pinilla-Plata A, Sayago-Silva J. Toxoplasmosis congénita, una mirada en la actualidad del tratamiento; revisión de la literatura. MedUNAB. 2019;22(1):51-63. doi: 10.29375/01237047.2612
Introduction. Congenital Toxoplasmosis constitutes a significant cause of neonatal morbimortality in underdeveloped countries like Colombia. It can cause prematurity, pathological after-effects and fetal loss. Screening expectant mothers and in turn, a timely and adequate treatment, reduce vertical transmission and its devastating effects. The objective is to present up-to-date scientific evidence about the pharmacological treatment of Congenital Toxoplasmosis. Methodology. A non-systematic search of databases was conducted: Pubmed, Medline, Clinical Key and Springer. Original and topic review articles were included dating from January 2014 to April 2019. Division of topics covered. Physiopathology and clinical pathology, diagnostic approach, prevention and treatment alternatives were addressed. Conclusions. At this time, pharmacological therapy is limited, management schemes are based on spiramycin or a combination of sulfadiazine/pyrimethamine and folinic acid; these molecules are not very well tolerated and exhibit a wide spectrum of adverse reactions apart from their toxic effects, thus it is necessary to conduct randomized studies to evaluate its effectiveness. Cómo citar: Rueda-Paez YS, Valbuena-Ruiz L, Quintero-Pimiento N, Pinilla-Plata A, Sayago-Silva J. Toxoplasmosis congénita, una mirada en la actualidad del tratamiento; revisión de la literatura. MedUNAB. 2019;22(1):51-63. doi: 10.29375/01237047.2612
Introdução. A toxoplasmose congênita é uma causa significativa de morbidade e mortalidade neonatal em países de baixa renda, como a Colômbia. Pode causar prematuridade, sequelas patológicas e perda fetal. A triagem em gestantes e, por sua vez, um tratamento oportuno e adequado diminui a transmissão vertical e suas consequências desastrosas. O objetivo é apresentar evidências científicas atualizadas sobre o tratamento farmacológico da Toxoplasmose Congênita. Metodologia. Foi realizada uma revisão não sistemática nas bases de dados: Pubmed, Medline, Clinical Key e Springer. Foram incluídos tanto artigos originais, quanto revisões de tópicos publicados de janeiro de 2014 até abril de 2019. Divisão dos tópicos discutidos. foram abordadas a fisiopatologia e a clínica, a abordagem diagnóstica, alternativas para prevenção e tratamento. Conclusões. Atualmente, a terapia farmacológica é limitada, os esquemas terapéuticos baseiam-se na espiramicina ou na combinação de sulfadiazina/pirimetamina e ácido folínico; estas moléculas não são totalmente toleradas e apresentam um amplo espectro de reações adversas secundárias aos seus efeitos tóxicos. É necessário realizar estudos randomizados para avaliar sua eficácia. Cómo citar: Rueda-Paez YS, Valbuena-Ruiz L, Quintero-Pimiento N, Pinilla-Plata A, Sayago-Silva J. Toxoplasmosis congénita, una mirada en la actualidad del tratamiento; revisión de la literatura. MedUNAB. 2019;22(1):51-63. doi: 10.29375/01237047.2612
Asunto(s)
Toxoplasmosis Congénita , Pirimetamina , Sulfadiazina , EspiramicinaRESUMEN
A toxoplasmose, causada pelo protozoário Toxoplasma gondii, apresenta complicações graves quando adquirida no período gestacional. No Brasil, a incidência de toxoplasmose congênita varia entre 4 a 10 casos para cada 10 mil nascidos vivos, com apresentação clínica variável, incluindo alterações oculares (como coriorretinite), neurológicas (como encefalite, microcefalia e macrocefalia), sistêmicas (hepatomegalia, icterícia) e óbito fetal/neonatal. O risco de transmissão e a gravidade das complicações têm comportamentos inversos em relação à idade gestacional. A taxa de transmissão ao feto é 14% no primeiro trimestre e 60% no terceiro trimestre. Já a gravidade, tende a ser maior nas infecções adquiridas no começo da gestação. A taxa de transmissão varia entre 50% a 60% em mães não tratadas e 20% a 30% nas que receberam tratamento durante a gestação. Por isso, a prevenção da infecção, rastreamento e diagnóstico precoce são fundamentais para evitar as complicações da toxoplasmose congênita. Esta guia apresenta informação que orienta a conduta para casos de toxoplasmose na gestação no contexto da Atenção Primária à Saúde, incluindo: Rastreamento, Transmissão e prevenção, Manifestações clínicas, Gestação após infecção aguda, Diagnóstico na gestante, Conduta durante o pré-natal na APS, Tratamento da gestante, Diagnóstico de infecção fetal, Diagnóstico de infecção congênita, Encaminhamento para serviço especializado.
Asunto(s)
Humanos , Toxoplasmosis Congénita/diagnóstico , Toxoplasmosis Congénita/prevención & control , Atención Prenatal , Atención Primaria de Salud , Derivación y Consulta , Espiramicina/uso terapéuticoRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Leishmaniasis Mucocutánea/diagnóstico , Granuloma/cirugía , Neoplasias de la Lengua/patología , Leishmaniasis Mucocutánea/complicaciones , Leishmaniasis Mucocutánea/patología , Neoplasias de la Lengua/tratamiento farmacológico , Espiramicina/administración & dosificación , Fluconazol/administración & dosificación , Anfotericina B/administración & dosificaciónRESUMEN
Resumen Introducción. La toxoplasmosis de la gestación es frecuente y grave. Hasta ahora no hay consenso sobre la utilidad del tratamiento para prevenir complicaciones oculares en el neonato. En la actualidad, uno de los medicamentos utilizados en las madres diagnosticadas es la espiramicina oral. Infortunadamente, en algunas mujeres gestantes no se hace el diagnóstico prenatal y, por esta u otras razones, no reciben el tratamiento. Objetivo. Describir la relación entre el tratamiento con espiramicina durante el embarazo en madres con toxoplasmosis de la gestación y la presentación de toxoplasmosis ocular en los recién nacidos. Materiales y métodos. Se llevó a cabo un estudio observacional descriptivo de serie de casos. Se evaluó una serie prospectiva de pacientes con toxoplasmosis de la gestación durante tres años de seguimiento en el Servicio de Retinología de la Clínica Universitaria Bolivariana de Medellín. Resultados. Se registraron 23 madres con diagnóstico de toxoplasmosis de la gestación. Quince de ellas (65 %) recibieron durante la gestación tratamiento con espiramicina en dosis de 3 g al día; uno de los neonatos (6,6 %) presentó toxoplasmosis ocular. De las ocho (35 %) pacientes que no recibieron tratamiento, cinco (62,5 %) tuvieron hijos con compromiso ocular por toxoplasma. La razón de momios (odds ratio, OR) del efecto protector contra dicho compromiso en los pacientes cuyas madres recibieron tratamiento fue de 0,04 (IC95% 0,00-0,67), con valor de p menor de 0,01 en la prueba exacta de Fisher. Solo se evidenció compromiso del sistema nervioso central por toxoplasmosis mediante las imágenes de tomografía o ecografía cerebral en dos (14 %) pacientes de las 14 en quienes se hicieron estos estudios. Los dos pacientes presentaron, además, compromiso ocular; ambos fueron diagnosticados en el momento del nacimiento y sus madres no habían recibido tratamiento prenatal. Conclusiones. Estos resultados evidencian que el tratamiento con espiramicina durante el embarazo en la toxoplasmosis de la gestación redujo en 96 % (IC95% 33-100 %) el riesgo relativo de presentar la enfermedad en el recién nacido.
Abstrat Introduction: Gestational toxoplasmosis is frequent and severe. There is still debate about the benefits of treatment against ocular manifestations in the newborn. Spiramycin treatment is used for this purpose, unfortunately prenatal diagnosis is sometimes delayed and pregnant women are not treated. Objective: To describe the relationship between treatment with spiramycin during pregnancy in mothers with gestational toxoplasmosis and development of ocular toxoplasmosis in newborns. Materials and methods: We conducted a descriptive study of a case series. We evaluated a prospective cohort of patients diagnosed with gestational toxoplasmosis during three years at the Retinology Service at the Clínica Universitaria Bolivariana in Medellín. Results: Gestational toxoplasmosis was found in 23 mothers; 15 (65%) were treated during pregnancy with 3 g per day of spiramycin, eight (35%) patients were untreated. In the treated group just one newborn developed ocular toxoplasmosis (6.6%), in contrast with five (62.5%) of the eight patients who did not receive treatment. These results suggest that pregnancy treatment reduces the relative risk of ocular toxoplasmosis in the newborn by 96% (95% CI: 33 - 100%). Only two (14%) of the patients who were evaluated, had nervous system involvement related to toxoplasmosis in CT scan or cerebral ultrasound. These two patients also developed ocular pathology and were diagnosed at the time of birth, so they did not received antenatal treatment. Conclusions: A protective effect was found against the ocular involvement in patients whose mother received treatment with spiramycin (OR=0.04;95% CI: 0.00-0.67), p<0.01 (Fisher's Exact Test).
Asunto(s)
Femenino , Humanos , Recién Nacido , Embarazo , Espiramicina/farmacología , Toxoplasmosis/epidemiología , Toxoplasmosis Congénita/tratamiento farmacológico , Diagnóstico Prenatal , Espiramicina/química , Toxoplasmosis/genética , Toxoplasmosis/prevención & control , Toxoplasmosis/terapia , Toxoplasmosis Congénita/diagnóstico , Toxoplasmosis Congénita/prevención & control , Toxoplasmosis Congénita/epidemiología , Estudios Prospectivos , ColombiaRESUMEN
Objetivo: conocer los resultados perinatales obtenidos en las pacientes con seroconversión para toxoplasma durante la gestación. Material y Métodos: estudio retrospectivo descriptivo de las gestaciones con seroconversión para toxoplasma durante el embarazo, entre los años 2004 y 2012. Las variables estudiadas hicieron referencia a las características gestacionales, serológicas y perinatales. El tratamiento de los datos se realizó con el programa estadístico SPSS versión 18 paraWindows. Resultados: la población a estudio englobó un total de 139 gestantes, de las cuales un 85% presentó la seroconversión para toxoplasma en el primer trimestre, el 11% en el segundo y el 4% restante en el tercer trimestre.Se realizó un análisis en tres grupos según el resultado de la avidez de la inmunoglobina G: débil (32%), intermedia (17%) y fuerte (50%). Sólo se registró un caso de toxoplasmosis neonatal, correspondiente al grupo de avidez débil, donde el recién nacido presenta actualmente una pérdida auditiva de tipo conductivo de 20 dB en el oído izquierdo y de 10 dB en el oído derecho. Conclusión: los resultados perinatales no son peores en las pacientes con seroconversión para toxoplasma durante la gestación. La tasa de transmisión vertical en nuestro centro fue baja (AU)
Objective: To determine the perinatal results obtained in patients with toxoplasma seroconversion during pregnancy. Material and Methods: Retrospective descriptive of pregnancies with toxoplasma seroconversion during pregnancy, between 2004 and 2012. Studied variables referred to gestational characteristics, serological and perinatal. The data processing was performed using SPSS version 18 for Windows. Results: The study population encompassed a total of 139 pregnant women, of which 85% had seroconversion for toxoplasma in the first quarter, 11% in the second and the remaining 4% in the third quarter. Analysis wasperformed in three groups according to the result of the inmunoglobulin G: weak (32%), intermediate (17%) and strong (50%). Only one case of neonatal toxoplasmosis, corresponding to the avidity weak group, where currently newborn.This Conductive hearing loss of 20 dB in the left ear and 10 dB in the right ear. Conclusion: Perinatal outcomes were not worse in patients with toxoplasma seroconversion during gestation. The vertical transmission rate at our center was low (AU)
Asunto(s)
Humanos , Femenino , Embarazo , Toxoplasmosis Congénita/complicaciones , Seroconversión , Inmunoglobulina G/análisis , Transmisión Vertical de Enfermedad Infecciosa/estadística & datos numéricos , Toxoplasma , Toxoplasma/aislamiento & purificación , Estudios Retrospectivos , Espiramicina/uso terapéutico , Edad Gestacional , AmniocentesisRESUMEN
Coagulase-negative staphylococci, particularly Staphylococcus epidermidis, can be regarded as potential reservoirs of resistance genes for pathogenic strains, e.g., Staphylococcus aureus. The aim of this study was to assess the prevalence of different resistance phenotypes to macrolide, lincosamide, and streptogramins B (MLSB) antibiotics among erythromycin-resistant S. epidermidis, together with the evaluation of genes promoting the following different types of MLSB resistance:ermA, ermB, ermC,msrA, mphC, and linA/A’. Susceptibility to spiramycin was also examined. Among 75 erythromycin-resistantS. epidermidis isolates, the most frequent phenotypes were macrolides and streptogramins B (MSB) and constitutive MLSB (cMLSB). Moreover, all strains with the cMLSB phenotype and the majority of inducible MLSB (iMLSB) isolates were resistant to spiramycin, whereas strains with the MSB phenotype were sensitive to this antibiotic. The D-shape zone of inhibition around the clindamycin disc near the spiramycin disc was found for some spiramycin-resistant strains with the iMLSB phenotype, suggesting an induction of resistance to clindamycin by this 16-membered macrolide. The most frequently isolated gene was ermC, irrespective of the MLSB resistance phenotype, whereas the most often noted gene combination wasermC, mphC, linA/A’. The results obtained showed that the genes responsible for different mechanisms of MLSB resistance in S. epidermidis generally coexist, often without the phenotypic expression of each of them.
Asunto(s)
Humanos , Farmacorresistencia Bacteriana Múltiple/genética , Genotipo , Lincosamidas/farmacología , Macrólidos/farmacología , Staphylococcus epidermidis/efectos de los fármacos , Staphylococcus epidermidis/genética , Estreptogramina Grupo B/farmacología , Clindamicina/farmacología , Pruebas Antimicrobianas de Difusión por Disco , Eritromicina/farmacología , Pruebas Genéticas/métodos , Lincomicina/farmacología , Fenotipo , Reacción en Cadena de la Polimerasa , Prevalencia , Espiramicina/farmacología , Staphylococcus epidermidis/aislamiento & purificaciónRESUMEN
4"-O-isovaleryltransferase gene (ist) was regulated by positive regulatory genes of midecamycin 4"-O-propionyltransferase gene (mpt) in Streptomyces lividans TK24. A BamH I ~8.0 kb fragment from Streptomyces mycarofaciens 1748 was proved that it contained mpt gene and linked with two positive regulatory genes, orf27 and orf28. Orf of mpt was replaced by orf of ist and linked with two regulatory genes or orf27 single, and individually cloned into the vectors pKC1139 or pWHM3 (high copy number), and then transformed into S. lividans TK24. The levels of mpt and ist expression were evaluated by the bio-tramsformation efficacy of spiramycin into 4"-O-acylspiramycins in these transformants. The results showed that 4"-O-isovalerylspiramycins could be detected only in the transformants containing the plasmids constructed with pWHM3. The efficacy of bio-transformation of the transformants containing two regulatory genes was higher than that of orf27 single. So, the positive regulatory genes system of mpt gene could enhance ist gene expression.
Asunto(s)
Aciltransferasas , Genética , Metabolismo , Proteínas Bacterianas , Genética , Metabolismo , Expresión Génica , Vectores Genéticos , Plásmidos , Espiramicina , Streptomyces , Genética , Streptomyces lividans , Metabolismo , Transformación GenéticaRESUMEN
Macrolide antibiotics are broad-spectrum, with activity against a range of Gram-positive, Gram-negative organisms and some anaerobes. The components of macrolide antibiotics are generally complicated. Therefore, it is very important to establish impurity profiles of these antibiotics to ensure their safety and process control. Compared with classical methods, the liquid chromatography-mass spectrometry method is particularly advantageous to characterize minor components at trace levels in terms of sensitivity, efficiency and selectivity, thus more and more widely used in establishments of impurity profiles. In this study, the general approaches to characterize minor components in complex pharmaceutical matrix, fragmentation pathways of 14- and 16-membered macrolide antibiotics and the establishment of the impurity profile of acetylspiramycin were given to provide valuable enlightenments to establish the impurity profiles of pharmaceutical products.
Asunto(s)
Antibacterianos , Química , Cromatografía Liquida , Contaminación de Medicamentos , Macrólidos , Química , Espectrometría de Masas , Espiramicina , QuímicaRESUMEN
Los estudios clínicos indican un efecto adicional beneficioso de la espiramicina cuando se la utiliza junto con el raspaje y alisado radicular. Hasta el presente, su efecto sobre la microbiota periodontal ha sido estudiado sólo con microscopio de campo oscuro. El objetivo del presente estudio fue evaluar el efecto de la espiramicina sobre Porphyromonas gingivalis y otros patógenos periodontales "clásicos", con la técnica de PCR, utilizando el gen 16S del ARNr. Participaron de este estudio clínico controlado randomizado 32 sujeros adultos, no fumadores, con enfermedad periodontal no tratada, con bolsas periodontales >- a 7mm. Se registraron parámetros clínicos en el día -15, 15, 30 y 90 de iniciado el estudio. Se analizó el biofilm periodontal subgingival con PCR, identificándose Prophyromonas gingivalis (Pg), Tannarella forsythia (Tf), Treponema denticola (Td) y Aggregatibacter actinomycetemcomitans (Aa) en el día 30 y 90. En el día 0, 25 sujetos positivos para Porphyromonas gingivalis se dividieron aleatoriamente en dos grupos: grupo Test (Espiramicina 7 días) y grupo control (Placebo 7 días). La espiramicina fue efectiva sobre Pg, Tf, Td. Hubo diferencias (p<0,05) con el grupo control. Ninguno de los grupos mostró diferencias para Aa. Estos datos indicarían que la Espiramicina fue efectiva sobre las bacterias que actualmente se asocian con periodontitis severas (Pg, Tf, Td) luego de la administración sistémica durante 7 días.
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Antibacterianos/farmacología , Espiramicina/farmacología , Periodontitis/microbiología , Periodontitis/tratamiento farmacológico , Porphyromonas gingivalisRESUMEN
Bitespiramycin, a group of 4"-O-acylated spiramycins with 4"-O-isovalerylspiramycins as the major components, was produced by recombinantspiramycin-producing strain Streptomyces spiramyceticus harboring a 4"-O-acyltransferase gene. The experiment was initially performed in synthetic medium with 0.5 g l-1 Valine, Isoleucine or Leucine feeding at 36 h cultivation. When valine was fed, the biological titer of bitespiramycin was 45.3 percent higher than that of the control group, but the relative content of total isovalerylspiramycin components decreased by 22.5 percent. In the case of ilecine, the biological titer of bitespiramycin and the total isovalerylspiramycins alone were 85 percent and 72.1 percent of the control group, respectively. In contrast, the relative content of other acylated spiramycins increased by 54.41 percent. However, leucine feeding increased the relative content of total isovalerylspiramycins by 41.9 percent while the biological titer of bitespiramycin was nearly equal to that of the control group. The improvement effect of leucine on the biosynthesis of isovalerylspiramycins was further confirmed by feeding of 2.0 g l-1 leucine to the culture with complex medium. After batch feeding with a total amount of 2.0 g l-1 leucine to the culture from 70 h to 90 h, the biological titer of bitespiramycin was almost unreduced, and the final relative content of total isovalerylspiramycins increased from 31.1 percent to 46.9 percent.